Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study
Aim To assess C-reactive protein to albumin ratio (CAR) before and after treatment with biological agents in patients with psoriasis to determine whether CAR can be used as an inflammation biomarker. Methods Medical records of patients with psoriasis treated with biological agents at the Department...
Gespeichert in:
| Veröffentlicht in: | Croatian medical journal 2020-08, Vol.61 (4), p.333-337 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 337 |
|---|---|
| container_issue | 4 |
| container_start_page | 333 |
| container_title | Croatian medical journal |
| container_volume | 61 |
| creator | Tamer, Funda Avci, Emine |
| description | Aim To assess C-reactive protein to albumin ratio (CAR) before and after treatment with biological agents in patients with psoriasis to determine whether CAR can be used as an inflammation biomarker. Methods Medical records of patients with psoriasis treated with biological agents at the Department of Dermatology, Gazi University Hospital were retrospectively evaluated between June 2018 and August 2019. The patients were divided into four groups based on the type of treatment (adalimumab, ustekinumab, infliximab, secukinumab). CAR was evaluated before and three months after treatment. Results The study enrolled 157 patients with psoriasis vulgaris (91 male) aged between 18 and 85. CAR significantly decreased in all treatment groups (adalimumab group P< 0.001; ustekinumab P = 0.006; infliximab P=0.007; secukinumab P < 0.001). The most prominent decrease in CAR was observed in patients treated with secukinumab (median CAR before treatment 1.52 [1.01-3.04] and after treatment 0.84 [0.62-0.99]). Conclusion CAR may be a good indicator of systemic inflammation in psoriasis patients treated with biological agents. |
| doi_str_mv | 10.3325/cmj.2020.61.333 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7480757</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A638407151</galeid><sourcerecordid>A638407151</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-dbc18c29c7838da69ac6a05889c3a438c87bfc6735808a426117934cd82c32583</originalsourceid><addsrcrecordid>eNptUsFu1DAQtRCILoUzV0tInMjWjhPHywGpWlFAqsQBOFsTx-m6jePIdhb6a3xdJ6RCrIR88MybN88z4yHkNWdbIcr6wvjbbclKtpUcAfGEbDjiheJSPiUbJmpR7GpWnZEXKd0yJFaVfE7ORKkUrwTfkN_fbJw93RfRgsnuaOkUQ7ZupDlQGNrZoxkhO_QSBTqGox2oG_sBvF_gkbYueIh3NiJMpxSig-QSnTBqx5xoRulsO_rT5QOFDgbnZw_tOzqnbO_cuDqLpPvl_tgwdjRZMz8G3-O70eYY0mTXGlOeu_uX5FkPQ7KvHu9z8uPq4_f95-L666cv-8vrwlSizkXXGq5MuTONEqoDuQMjgdVK7YyASiijmrY3shG1YgqqUnLe7ERlOlUaHLES5-TDqjvNrbedwaYiDHqKWGy81wGcPo2M7qBvwlE3lWJN3aDAm1XgBgarsdGANONdMvpSClWxhtccWdv_sPB01jsTRts7xE8S3v6TcLAw5EMKw7x8SjolXqxEgyNM0fZ_a-dML2ukcY30skZacgSEeABy6b2U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Tamer, Funda ; Avci, Emine</creator><creatorcontrib>Tamer, Funda ; Avci, Emine</creatorcontrib><description>Aim To assess C-reactive protein to albumin ratio (CAR) before and after treatment with biological agents in patients with psoriasis to determine whether CAR can be used as an inflammation biomarker. Methods Medical records of patients with psoriasis treated with biological agents at the Department of Dermatology, Gazi University Hospital were retrospectively evaluated between June 2018 and August 2019. The patients were divided into four groups based on the type of treatment (adalimumab, ustekinumab, infliximab, secukinumab). CAR was evaluated before and three months after treatment. Results The study enrolled 157 patients with psoriasis vulgaris (91 male) aged between 18 and 85. CAR significantly decreased in all treatment groups (adalimumab group P< 0.001; ustekinumab P = 0.006; infliximab P=0.007; secukinumab P < 0.001). The most prominent decrease in CAR was observed in patients treated with secukinumab (median CAR before treatment 1.52 [1.01-3.04] and after treatment 0.84 [0.62-0.99]). Conclusion CAR may be a good indicator of systemic inflammation in psoriasis patients treated with biological agents.</description><identifier>ISSN: 0353-9504</identifier><identifier>EISSN: 1332-8166</identifier><identifier>DOI: 10.3325/cmj.2020.61.333</identifier><identifier>PMID: 32881431</identifier><language>eng</language><publisher>Sveuciliste U Zagrebu</publisher><subject>Albumin ; C-reactive protein ; Care and treatment ; Dermatologic agents ; Evidence-based medicine ; Inflammation ; Infliximab ; Medical research ; Monoclonal antibodies ; Psoriasis</subject><ispartof>Croatian medical journal, 2020-08, Vol.61 (4), p.333-337</ispartof><rights>COPYRIGHT 2020 Sveuciliste U Zagrebu</rights><rights>Copyright © 2020 by the Croatian Medical Journal. All rights reserved. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-dbc18c29c7838da69ac6a05889c3a438c87bfc6735808a426117934cd82c32583</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480757/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480757/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Tamer, Funda</creatorcontrib><creatorcontrib>Avci, Emine</creatorcontrib><title>Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study</title><title>Croatian medical journal</title><description>Aim To assess C-reactive protein to albumin ratio (CAR) before and after treatment with biological agents in patients with psoriasis to determine whether CAR can be used as an inflammation biomarker. Methods Medical records of patients with psoriasis treated with biological agents at the Department of Dermatology, Gazi University Hospital were retrospectively evaluated between June 2018 and August 2019. The patients were divided into four groups based on the type of treatment (adalimumab, ustekinumab, infliximab, secukinumab). CAR was evaluated before and three months after treatment. Results The study enrolled 157 patients with psoriasis vulgaris (91 male) aged between 18 and 85. CAR significantly decreased in all treatment groups (adalimumab group P< 0.001; ustekinumab P = 0.006; infliximab P=0.007; secukinumab P < 0.001). The most prominent decrease in CAR was observed in patients treated with secukinumab (median CAR before treatment 1.52 [1.01-3.04] and after treatment 0.84 [0.62-0.99]). Conclusion CAR may be a good indicator of systemic inflammation in psoriasis patients treated with biological agents.</description><subject>Albumin</subject><subject>C-reactive protein</subject><subject>Care and treatment</subject><subject>Dermatologic agents</subject><subject>Evidence-based medicine</subject><subject>Inflammation</subject><subject>Infliximab</subject><subject>Medical research</subject><subject>Monoclonal antibodies</subject><subject>Psoriasis</subject><issn>0353-9504</issn><issn>1332-8166</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNptUsFu1DAQtRCILoUzV0tInMjWjhPHywGpWlFAqsQBOFsTx-m6jePIdhb6a3xdJ6RCrIR88MybN88z4yHkNWdbIcr6wvjbbclKtpUcAfGEbDjiheJSPiUbJmpR7GpWnZEXKd0yJFaVfE7ORKkUrwTfkN_fbJw93RfRgsnuaOkUQ7ZupDlQGNrZoxkhO_QSBTqGox2oG_sBvF_gkbYueIh3NiJMpxSig-QSnTBqx5xoRulsO_rT5QOFDgbnZw_tOzqnbO_cuDqLpPvl_tgwdjRZMz8G3-O70eYY0mTXGlOeu_uX5FkPQ7KvHu9z8uPq4_f95-L666cv-8vrwlSizkXXGq5MuTONEqoDuQMjgdVK7YyASiijmrY3shG1YgqqUnLe7ERlOlUaHLES5-TDqjvNrbedwaYiDHqKWGy81wGcPo2M7qBvwlE3lWJN3aDAm1XgBgarsdGANONdMvpSClWxhtccWdv_sPB01jsTRts7xE8S3v6TcLAw5EMKw7x8SjolXqxEgyNM0fZ_a-dML2ukcY30skZacgSEeABy6b2U</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Tamer, Funda</creator><creator>Avci, Emine</creator><general>Sveuciliste U Zagrebu</general><general>Croatian Medical Schools</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20200801</creationdate><title>Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study</title><author>Tamer, Funda ; Avci, Emine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-dbc18c29c7838da69ac6a05889c3a438c87bfc6735808a426117934cd82c32583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Albumin</topic><topic>C-reactive protein</topic><topic>Care and treatment</topic><topic>Dermatologic agents</topic><topic>Evidence-based medicine</topic><topic>Inflammation</topic><topic>Infliximab</topic><topic>Medical research</topic><topic>Monoclonal antibodies</topic><topic>Psoriasis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tamer, Funda</creatorcontrib><creatorcontrib>Avci, Emine</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Croatian medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tamer, Funda</au><au>Avci, Emine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study</atitle><jtitle>Croatian medical journal</jtitle><date>2020-08-01</date><risdate>2020</risdate><volume>61</volume><issue>4</issue><spage>333</spage><epage>337</epage><pages>333-337</pages><issn>0353-9504</issn><eissn>1332-8166</eissn><abstract>Aim To assess C-reactive protein to albumin ratio (CAR) before and after treatment with biological agents in patients with psoriasis to determine whether CAR can be used as an inflammation biomarker. Methods Medical records of patients with psoriasis treated with biological agents at the Department of Dermatology, Gazi University Hospital were retrospectively evaluated between June 2018 and August 2019. The patients were divided into four groups based on the type of treatment (adalimumab, ustekinumab, infliximab, secukinumab). CAR was evaluated before and three months after treatment. Results The study enrolled 157 patients with psoriasis vulgaris (91 male) aged between 18 and 85. CAR significantly decreased in all treatment groups (adalimumab group P< 0.001; ustekinumab P = 0.006; infliximab P=0.007; secukinumab P < 0.001). The most prominent decrease in CAR was observed in patients treated with secukinumab (median CAR before treatment 1.52 [1.01-3.04] and after treatment 0.84 [0.62-0.99]). Conclusion CAR may be a good indicator of systemic inflammation in psoriasis patients treated with biological agents.</abstract><pub>Sveuciliste U Zagrebu</pub><pmid>32881431</pmid><doi>10.3325/cmj.2020.61.333</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0353-9504 |
| ispartof | Croatian medical journal, 2020-08, Vol.61 (4), p.333-337 |
| issn | 0353-9504 1332-8166 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7480757 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Albumin C-reactive protein Care and treatment Dermatologic agents Evidence-based medicine Inflammation Infliximab Medical research Monoclonal antibodies Psoriasis |
| title | Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T01%3A59%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20C-reactive%20protein%20to%20albumin%20ratio%20as%20a%20novel%20inflammation%20biomarker%20in%20psoriasis%20patients%20treated%20with%20adalimumab,%20ustekinumab,%20infliximab,%20and%20secukinumab:%20a%20retrospective%20study&rft.jtitle=Croatian%20medical%20journal&rft.au=Tamer,%20Funda&rft.date=2020-08-01&rft.volume=61&rft.issue=4&rft.spage=333&rft.epage=337&rft.pages=333-337&rft.issn=0353-9504&rft.eissn=1332-8166&rft_id=info:doi/10.3325/cmj.2020.61.333&rft_dat=%3Cgale_pubme%3EA638407151%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32881431&rft_galeid=A638407151&rfr_iscdi=true |